Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanofi, in collaboration with Teva Branded Pharmaceutical Products R&D LLC, is conducting a Phase 3 clinical study titled ‘A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Phase 3, Induction Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis.’ The study aims to assess the effectiveness and safety of the drug Duvakitug for patients suffering from this chronic inflammatory bowel disease.
The study is testing Duvakitug, administered as a subcutaneous injection, in two different doses against a placebo. The goal is to determine the drug’s efficacy in inducing remission in ulcerative colitis patients.
This interventional study employs a randomized, parallel assignment model with quadruple masking (participant, care provider, investigator, outcomes assessor) to ensure unbiased results. The primary purpose is treatment-focused.
The study began on September 15, 2025, with the last update submitted on October 1, 2025. These dates are crucial as they mark the progression and current status of the study, which is still recruiting participants.
Sanofi’s ongoing research could significantly impact its market position, potentially boosting investor confidence if the results are favorable. The study’s outcome may also influence the competitive landscape in the ulcerative colitis treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.